Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC) 2018, 'A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process', British Journal of Dermatology, bind 179, nr. 3, s. 642-650. https://doi.org/10.1111/bjd.16672

APA

HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC) (2018). A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. British Journal of Dermatology, 179(3), 642-650. https://doi.org/10.1111/bjd.16672

CBE

HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC). 2018. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. British Journal of Dermatology. 179(3):642-650. https://doi.org/10.1111/bjd.16672

MLA

HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC). "A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process". British Journal of Dermatology. 2018, 179(3). 642-650. https://doi.org/10.1111/bjd.16672

Vancouver

HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC). A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. British Journal of Dermatology. 2018 sep;179(3):642-650. https://doi.org/10.1111/bjd.16672

Author

HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC). / A core domain set for hidradenitis suppurativa trial outcomes : an international Delphi process. I: British Journal of Dermatology. 2018 ; Bind 179, Nr. 3. s. 642-650.

Bibtex

@article{83839cf9607843aab64f936f9d75e579,
title = "A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process",
abstract = "BACKGROUND: There is no consensus on core outcome domains for hidradenitis suppurativa (HS). Heterogeneous outcome measure instruments in clinical trials likely leads to outcome-reporting bias and limits the ability to synthesize evidence.OBJECTIVES: To achieve global multistakeholder consensus on a core outcome set (COS) of domains regarding what to measure in clinical trials for HS.METHODS: Six stakeholder groups participated in a Delphi process that included five anonymous e-Delphi rounds and four face-to-face consensus meetings to reach consensus on the final COS. The aim was for a 1 : 1 ratio of patients to healthcare professionals (HCPs).RESULTS: A total of 41 patients and 52 HCPs from 19 countries in four continents participated in the consensus process, which yielded a final COS that included five domains: pain, physical signs, HS-specific quality of life, global assessment and progression of course. A sixth domain, symptoms, was highly supported by patients and not by HCPs but is recommended for the core domain set.CONCLUSIONS: Routine adoption of the COS in future HS trials should ensure that core outcomes of importance to both patients and HCPs are collected.",
author = "L Thorlacius and Ingram, {J R} and B Villumsen and S Esmann and Kirby, {J S} and Gottlieb, {A B} and Merola, {J F} and R Dellavalle and Nielsen, {S M} and R Christensen and A Garg and Jemec, {G B E} and {HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC)}",
note = "{\textcopyright} 2018 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.",
year = "2018",
month = sep,
doi = "10.1111/bjd.16672",
language = "English",
volume = "179",
pages = "642--650",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "3",

}

RIS

TY - JOUR

T1 - A core domain set for hidradenitis suppurativa trial outcomes

T2 - an international Delphi process

AU - Thorlacius, L

AU - Ingram, J R

AU - Villumsen, B

AU - Esmann, S

AU - Kirby, J S

AU - Gottlieb, A B

AU - Merola, J F

AU - Dellavalle, R

AU - Nielsen, S M

AU - Christensen, R

AU - Garg, A

AU - Jemec, G B E

AU - HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC)

N1 - © 2018 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

PY - 2018/9

Y1 - 2018/9

N2 - BACKGROUND: There is no consensus on core outcome domains for hidradenitis suppurativa (HS). Heterogeneous outcome measure instruments in clinical trials likely leads to outcome-reporting bias and limits the ability to synthesize evidence.OBJECTIVES: To achieve global multistakeholder consensus on a core outcome set (COS) of domains regarding what to measure in clinical trials for HS.METHODS: Six stakeholder groups participated in a Delphi process that included five anonymous e-Delphi rounds and four face-to-face consensus meetings to reach consensus on the final COS. The aim was for a 1 : 1 ratio of patients to healthcare professionals (HCPs).RESULTS: A total of 41 patients and 52 HCPs from 19 countries in four continents participated in the consensus process, which yielded a final COS that included five domains: pain, physical signs, HS-specific quality of life, global assessment and progression of course. A sixth domain, symptoms, was highly supported by patients and not by HCPs but is recommended for the core domain set.CONCLUSIONS: Routine adoption of the COS in future HS trials should ensure that core outcomes of importance to both patients and HCPs are collected.

AB - BACKGROUND: There is no consensus on core outcome domains for hidradenitis suppurativa (HS). Heterogeneous outcome measure instruments in clinical trials likely leads to outcome-reporting bias and limits the ability to synthesize evidence.OBJECTIVES: To achieve global multistakeholder consensus on a core outcome set (COS) of domains regarding what to measure in clinical trials for HS.METHODS: Six stakeholder groups participated in a Delphi process that included five anonymous e-Delphi rounds and four face-to-face consensus meetings to reach consensus on the final COS. The aim was for a 1 : 1 ratio of patients to healthcare professionals (HCPs).RESULTS: A total of 41 patients and 52 HCPs from 19 countries in four continents participated in the consensus process, which yielded a final COS that included five domains: pain, physical signs, HS-specific quality of life, global assessment and progression of course. A sixth domain, symptoms, was highly supported by patients and not by HCPs but is recommended for the core domain set.CONCLUSIONS: Routine adoption of the COS in future HS trials should ensure that core outcomes of importance to both patients and HCPs are collected.

U2 - 10.1111/bjd.16672

DO - 10.1111/bjd.16672

M3 - Journal article

C2 - 29654696

VL - 179

SP - 642

EP - 650

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 3

ER -

ID: 56061941